Key points

In Infants

• The mandatory meningococcal ACWY vaccination program, implemented on January 1, 2025, for infants following an increase in cases of invasive meningococcal disease (IMD) caused by serogroups W and Y, has resulted in high vaccination coverage, with nearly 90% of infants born in 2025 having received the first dose of the meningococcal ACWY vaccine. Among children born in 2024, before the replacement of the meningococcal C vaccine with the ACWY vaccine, 82% had received at least one dose of the tetravalent ACWY meningococcal vaccine by the age of 21 months. This vaccination coverage is lower than that estimated in 2024 for meningococcal C. It should be noted that vaccination started with a monovalent C vaccine before January 1, 2025, in infants must be continued with a tetravalent ACWY vaccine.
• In 2025, the year mandatory vaccination against meningococcal B was implemented for infants up to age 2, vaccination coverage against these infections has increased significantly, with 66% of infants born in 2024 (aged 21 months) up to date on their vaccinations (compared to 55% in 2024).
• Vaccination coverage for other mandatory infant vaccinations is generally high, with levels approaching the 95% target set by the World Health Organization (WHO) for the hexavalent vaccine and pneumococcal vaccine (92% for 3 doses at 21 months). For the measles-mumps-rubella vaccine, 1-dose vaccination coverage is 96% but drops to 88% for 2 doses. Nevertheless, given the resurgence of measles virus circulation in France since 2024, it is important to note that two-dose vaccination coverage must reach the 95% target to interrupt the circulation of the virus, which can lead to deaths among vulnerable individuals. Verifying and updating this vaccination status is essential for both children and young adults.

In adolescents and young adults

• Given the potential severity and increased frequency of IIMs during adolescence, vaccination against meningococcal ACWY is recommended for adolescents, with catch-up vaccination for young adults. In 2025, only 17% of 11- to 14-year-olds and 7% of 15- to 24-year-olds had received one dose of this vaccine. Vaccination against meningococcal ACWY must be intensified in this age group. Integrating this vaccination into campaigns conducted in middle schools starting in 2026 will help strengthen protection for young people against these infections. Efforts to improve vaccination coverage must continue in order to achieve herd immunity and reduce the circulation of meningococci in other age groups.
• Vaccination coverage against human papillomavirus (HPV) infections continues to increase, with 52% of 16-year-old girls and 33% of 16-year-old boys having received a full vaccination series. The gap in vaccination coverage between girls and boys continues to narrow. This progress is encouraging, but vaccination coverage remains largely insufficient to reduce the incidence of cancers linked to these infections. The national target set by the 10-year cancer control strategy is 80% for both girls and boys by 2030. Efforts must therefore continue to accelerate the uptake of HPV vaccination, particularly through vaccination campaigns in middle schools and by reinforcing messages about the importance of vaccinating boys.
  Vaccinating boys is just as essential as vaccinating girls: it contributes to equitable and sustainable protection.

Vaccination Uptake

According to the 2024 Santé publique France Barometer, vaccination uptake remains high in the region, particularly among young people, with 87% of 18- to 25-year-olds stating they are in favor of vaccination in general.